- Home
- SENEA vs TNGX Comparison
SENEA vs TNGX Comparison
Compare SENEA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- TNGX
- Stock Information
- Founded
- SENEA 1949
- TNGX 2014
- Country
- SENEA United States
- TNGX United States
- Employees
- SENEA N/A
- TNGX N/A
- Industry
- SENEA Packaged Foods
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- TNGX Health Care
- Exchange
- SENEA Nasdaq
- TNGX Nasdaq
- Market Cap
- SENEA 772.5M
- TNGX 723.2M
- IPO Year
- SENEA N/A
- TNGX N/A
- Fundamental
- Price
- SENEA $111.40
- TNGX $6.94
- Analyst Decision
- SENEA
- TNGX Strong Buy
- Analyst Count
- SENEA 0
- TNGX 6
- Target Price
- SENEA N/A
- TNGX $10.00
- AVG Volume (30 Days)
- SENEA 54.3K
- TNGX 1.3M
- Earning Date
- SENEA 11-05-2025
- TNGX 11-05-2025
- Dividend Yield
- SENEA N/A
- TNGX N/A
- EPS Growth
- SENEA N/A
- TNGX N/A
- EPS
- SENEA 6.24
- TNGX N/A
- Revenue
- SENEA $1,571,618,000.00
- TNGX $24,296,000.00
- Revenue This Year
- SENEA N/A
- TNGX $6.56
- Revenue Next Year
- SENEA N/A
- TNGX N/A
- P/E Ratio
- SENEA $17.86
- TNGX N/A
- Revenue Growth
- SENEA 7.30
- TNGX N/A
- 52 Week Low
- SENEA $59.21
- TNGX $1.03
- 52 Week High
- SENEA $115.40
- TNGX $11.92
- Technical
- Relative Strength Index (RSI)
- SENEA 61.71
- TNGX 56.91
- Support Level
- SENEA $111.43
- TNGX $6.28
- Resistance Level
- SENEA $115.00
- TNGX $7.05
- Average True Range (ATR)
- SENEA 2.53
- TNGX 0.41
- MACD
- SENEA 0.20
- TNGX -0.04
- Stochastic Oscillator
- SENEA 68.30
- TNGX 57.89
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.